Inhaled nitric oxide in mechanically ventilated patients with COVID-19
| Autor: | Alessandro Protti, Gianluca Castellani, Elena Costantini, Michele Ferrari, Alessandro Santini, Valerio Rendiniello, G. Iapichino, Davide T. Andreis, Maurizio Cecconi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Mechanical ventilation
medicine.medical_specialty ARDS Lung business.industry medicine.medical_treatment medicine.disease Critical Care and Intensive Care Medicine Intensive care unit Article Hypoxemia law.invention medicine.anatomical_structure Respiratory failure law Internal medicine Extracorporeal membrane oxygenation medicine Cardiology medicine.symptom business Positive end-expiratory pressure |
| Zdroj: | Journal of Critical Care |
| ISSN: | 1557-8615 0883-9441 |
| Popis: | Death from the novel coronavirus disease (COVID-19) predominantly occurs by refractory hypoxemia [1]. Some Authors have suggested that this type of respiratory failure differs from typical Acute Respiratory Distress Syndrome (ARDS) [2]. Patients with COVID-19 can present with (i) higher respiratory system compliance, and (ii) lower amount of non-ventilated lung tissue than expected given the severity of hypoxemia. These two elements may suggest a different primary cause of gas exchange impairment in COVID-19 compared to ARDS of another origin: excessive perfusion of small non-normally ventilated lung regions rather than a large anatomical shunt [3]. In line with this model, a recent series has revealed the presence of diffuse pulmonary endothelial injury and microthrombosis in COVID-19 lung pathology [4]. Given the novelty of COVID-19, its treatment is currently grounded on our knowledge of ARDS. Modern supportive therapy of ARDS generally consists of endotracheal intubation and mechanical ventilation with supplemental oxygen and Positive End Expiratory Pressure (PEEP), along with muscle paralysis, prone positioning, and ExtraCorporeal Membrane Oxygenation (ECMO) for the most severe cases [5,6]. Inhaled nitric oxide (iNO) can be considered as rescue therapy for hypoxemia due to its potent vasodilator effect on the pulmonary circulation [7]. International guidelines [5], and experts in the field [6,[8], [9], [10]], all suggest considering iNO even for refractory hypoxemia due to COVID-19. However, there are no strong clinical data to support this indication. Herein we describe the response to iNO in a small group of mechanically ventilated patients with severe COVID admitted to our Intensive Care Unit. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect